The forgotten survivor: A comprehensive review on Non-Hodgkin lymphoma survivorship.
Mohamad S AlabdaljabarUrshila DuraniCarrie A ThompsonLouis S ConstineShahrukh K HashmiPublished in: American journal of hematology (2022)
The number of non-Hodgkin lymphoma (NHL) survivors is increasing. With the advancement of NHL therapies, it is crucial to focus on the challenges these survivors may face. Three main categories are to be considered in NHL survivorship, including quality of life and uncertainty about the future, possible physical health complications (including cardiovascular disease, infertility, and subsequent neoplasms), and the impact of novel NHL treatments and their potential complications. The latter includes CAR T-cell therapy, monoclonal antibodies, checkpoint inhibitors, and hematopoietic stem cell transplantation. In this report, we aim to shed the light on these aspects and to discuss survivorship care plan for NHL.
Keyphrases
- cell therapy
- cardiovascular disease
- healthcare
- childhood cancer
- young adults
- mental health
- public health
- risk factors
- palliative care
- dna damage
- physical activity
- mesenchymal stem cells
- stem cells
- acute myeloid leukemia
- quality improvement
- type diabetes
- health information
- coronary artery disease
- insulin resistance
- pain management
- oxidative stress
- health insurance
- social media
- cardiovascular events
- affordable care act
- cardiovascular risk factors